Skip to content

Comparison of the effect of ketorolac and intravenous lidocaine on fentanyl-induced cough in surgery

Comparison of the effect of ketorolac and intravenous lidocaine on fentanyl-induced cough in patients undergoing elective surgery: a Double-blind clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220102053599N1
Enrollment
210
Registered
2022-06-25
Start date
2022-04-21
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fentanyl induced Cough. Cough

Interventions

Intervention 1: Intervention group No.1: The group receiving 1mg / kg intravenous lidocaine 2%(100mg/5ml, Caspian,Tamin,RASHT.IRAN) 3 minutes before intravenous fentanyl ( fentanyl citrate,0.5mg/10ml

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: aged 18 to 60 years, with and with, who any gender ASA 1 or 2 referred to Firoozgar and Hazrat Rasul-e Akram hospitals and are candidates for elective surgery that lasts more than an hour in the period of April 2022 to June 2022

Exclusion criteria

Exclusion criteria: Preoperative pulmonary emphysema Bronchial asthma History of upper respiratory infection during the last 2 weeks Smoking Hypertension Coronary artery disease Has a chronic cough that makes it difficult to diagnose fentanyl-induced cough High pressure inside the eyes, brain or abdomen Taking anti-anxiety and anti-depressant drugs before surgery Taking anti-cough medicines (codeine, dextromethorphan, baclofen, steroids or bronchodilators) during the last week BMI above 28 kg/m2 History of chronic opioid use Taking cough medicines (ACEI & ABR) History of GERD or peptic ulcer History of kidney or liver disease Pregnancy or breastfeeding Known allergy to fentanyl or ketorolac G6PD deficiency disease High risk of GIB Patient reluctance

Design outcomes

Primary

MeasureTime frame
Cough. Timepoint: Within 90 seconds of fentanyl injection. Method of measurement: observation.

Secondary

MeasureTime frame
Cough Intensity. Timepoint: Within 90 seconds of fentanyl injection. Method of measurement: Observation.;Cough start time. Timepoint: Within 90 seconds of fentanyl injection. Method of measurement: Stopwatch.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Tahzibi

Iran University of Medical Sciences

Sara.tahzibi@gmail.com+98 21 5528 8568

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026